Single-cell RNA sequencing reveals spatiotemporal heterogeneity and malignant progression in pancreatic neuroendocrine tumor.
Zhou Y, Liu S, Liu C, Yang J, Lin Q, Zheng S, Chen C, Zhou Q, Chen R.
Int J Biol Sci. 2021 Aug 28;17(14):3760-3775. doi: 10.7150/ijbs.61717. eCollection 2021.
Spatially restricted tumour-associated and host-associated immune drivers correlate with the recurrence sites of pancreatic cancer.
Karamitopoulou E, Wenning AS, Acharjee A, Zlobec I, Aeschbacher P, Perren A, Gloor B.
Gut. 2023 Aug;72(8):1523-1533. doi: 10.1136/gutjnl-2022-329371. Epub 2023 Feb 15.
Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors.
Heidrich I, Deitert B, Werner S, Pantel K.
Cancer Metastasis Rev. 2023 Mar;42(1):161-182. doi: 10.1007/s10555-022-10075-x. Epub 2023 Jan 6.
Tumor markers.
Seleznick MJ.
Prim Care. 1992 Dec;19(4):715-26.
Pattern recognition of tumor dormancy and relapse beyond cell-intrinsic and cell-extrinsic pathways.
Manjili MH, Khazaie K.
Semin Cancer Biol. 2022 Jan;78:1-4. doi: 10.1016/j.semcancer.2021.12.008. Epub 2022 Jan 3.
Malignant pericardial effusion.
Burazor I, Imazio M, Markel G, Adler Y.
Cardiology. 2013;124(4):224-32. doi: 10.1159/000348559. Epub 2013 Apr 5.
Trousseau's syndrome.
Callander N, Rapaport SI.
West J Med. 1993 Apr;158(4):364-71.
Presence of a Malignant Tumor as a Novel Predictive Factor for Repeated Recurrences of Chronic Subdural Hematoma.
Hori YS, Aoi M, Oda K, Fukuhara T.
World Neurosurg. 2017 Sep;105:714-719. doi: 10.1016/j.wneu.2017.06.043. Epub 2017 Jun 20.
Esthesioneuroblastoma.
Elkon D, Hightower SI, Lim ML, Cantrell RW, Constable WC.
Cancer. 1979 Sep;44(3):1087-94. doi: 10.1002/1097-0142(197909)44:3<1087::aid-cncr2820440343>3.0.co;2-a.
Outcome after bilateral deep vein thrombosis.
Fürbringer-Schwarz A, Janscak M, Jeanneret-Gris CR.
Vasa. 2022 Nov;51(6):372-376. doi: 10.1024/0301-1526/a001030. Epub 2022 Sep 23.
